Skechers Collaborates With Influential Artist Ricardo Cavolo

Skechers Collaborates With Influential Artist Ricardo Cavolo

Skechers announces the second chapter of its Visual Artist Series with the dynamic imagery of Skechers x Ricardo Cavolo

MADRID–(BUSINESS WIRE)–
Skechers is giving its Visual Artist Series a vibrant burst of energy with the eclectic cast behind one of Spain’s most influential artists, Ricardo Cavolo. The new Skechers x Ricardo Cavolo footwear capsule for women features the illustrator’s renowned flaming heart and eye imagery on a curated selection of top styles and comfort technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231005672240/en/

The latest in the Skechers Visual Artist Series, the Skechers x Ricardo Cavolo collection reinvents the brand’s iconic profiles with one of Spain’s most influential artists. (Graphic: Business Wire)

The latest in the Skechers Visual Artist Series, the Skechers x Ricardo Cavolo collection reinvents the brand’s iconic profiles with one of Spain’s most influential artists. (Graphic: Business Wire)

“My art tells stories of characters and their experiences through images that transcend culture and time,” said Ricardo Cavolo. “To see them continue their journey into this new dimension, where they now walk among us, is such a beautiful concept. It’s lovely to see Skechers celebrating art, and how they’re bringing artists and the fashion industry together to give us this incredible experience.”

“Ricardo Cavolo’s art is one of a kind. Fiery, direct and straight to the heart—literally. You can feel it the moment you see it—both in his images and on the collection’s uppers, which he personally designed,” said Michael Greenberg, president of Skechers. “In a world where conversations are exploring how best to protect and nurture our creative voice, we are proud to work hand-in-hand with great talent through our Visual Artist Series and show how their ingenuity inspires us. Cavolo’s symbols of love, empathy and hope are all of this, personified.”

A multimedia artisan known for connecting folk and traditional arts with spiritual imagery and modern tattoo culture, Cavolo transforms timeless icons into a dynamic narrative, focusing on portraiture and playfully depicting protagonists through symmetry and symbolism. Known for his illustrations, publications, fashion collaborations and wide range of globally commissioned works, Cavolo’s art has appeared on public murals and in exhibitions from Paris to Moscow, Mexico City and Hong Kong.

The Skechers x Ricardo Cavolo capsule is the second to debut in Skechers’ Visual Artist Series. Launched by American artist and designer Jen Stark’s hypnotic collection of iconic drip patterns this summer, the brand’s gallery of wearable art spotlights visionaries’ distinct designs on Skechers product in a run of launches through 2024. The Skechers x Ricardo Cavolo limited-edition capsule of three unique styles is now available in Spain at skechers.es, the Skechers store at Gran Vía 31 and its shop-in-shop at El Corte Inglés in Madrid, and the brand’s retail location at Portaferrissa 25 in Barcelona—and will roll out to Skechers retail stores and websites in the U.S. and select global markets.

About Skechers USA Iberia, S.L. and Skechers U.S.A., Inc.

Skechers USA Iberia, S.L. is a subsidiary of Skechers U.S.A., Inc. (NYSE:SKX), a Fortune 500® company based in Southern California. Skechers designs, develops and markets a diverse range of lifestyle and performance footwear, apparel and accessories for men, women and children. Collections from The Comfort Technology Company™ are available in 180 countries and territories through department and specialty stores, and direct to consumers through digital stores and over 4,700 Company- and third-party-owned physical retail stores. The Company manages its international business through a network of wholly-owned subsidiaries, joint venture partners, and distributors. For more information, please visit about.skechers.com and follow us on Facebook, Instagram and TikTok.

This announcement contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include, without limitation, Skechers’ future domestic and international growth, financial results and operations including expected net sales and earnings, its development of new products, future demand for its products, its planned domestic and international expansion, opening of new stores and additional expenditures, and advertising and marketing initiatives. Forward-looking statements can be identified by the use of forward-looking language such as “believe,” “anticipate,” “expect,” “estimate,” “intend,” “plan,” “project,” “will,” “could,” “may,” “might,” or any variations of such words with similar meanings. Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements. Factors that might cause or contribute to such differences include the disruption of business and operations due to the COVID-19 pandemic; delays or disruptions in our supply chain; international economic, political and market conditions including the effects of inflation and foreign currency exchange rate fluctuations around the world, the challenging consumer retail markets in the United States and the impact of Russia’s war with Ukraine; sustaining, managing and forecasting costs and proper inventory levels; losing any significant customers; decreased demand by industry retailers and cancellation of order commitments due to the lack of popularity of particular designs and/or categories of products; maintaining brand image and intense competition among sellers of footwear for consumers, especially in the highly competitive performance footwear market; anticipating, identifying, interpreting or forecasting changes in fashion trends, consumer demand for the products and the various market factors described above; sales levels during the spring, back-to-school and holiday selling seasons; and other factors referenced or incorporated by reference in Skechers’ annual report on Form 10-K for the year ended December 31, 2022 and its quarterly reports on Form 10-Q in 2023. Taking these and other risk factors associated with the COVID-19 pandemic into consideration, the dynamic nature of these circumstances means that what is stated in this press release could change at any time, and as a result, actual results could differ materially from those contemplated by such forward-looking statements. The risks included here are not exhaustive. Skechers operates in a very competitive and rapidly changing environment. New risks emerge from time to time and we cannot predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, you should not place undue reliance on forward-looking statements as a prediction of actual results. Moreover, reported results should not be considered an indication of future performance.

NOHO COMUNICACIÓN

Beatriz Lombana ([email protected])

Abigail Campos ([email protected])

91 534 30 90

KEYWORDS: Spain Europe

INDUSTRY KEYWORDS: Women Department Stores Arts/Museums Entertainment Specialty Fashion Consumer Retail Footwear Online Retail

MEDIA:

Logo
Logo
Photo
Photo
The latest in the Skechers Visual Artist Series, the Skechers x Ricardo Cavolo collection reinvents the brand’s iconic profiles with one of Spain’s most influential artists. (Graphic: Business Wire)

Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation

Vivoryon Therapeutics N.V. Announces Virtual R&D Event with

Key Opinion Leaders and Upcoming Conference Participation

Halle (Saale) / Munich, Germany, October 5, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced its plans to host a Virtual R&D Event with Key Opinion Leaders (KOLs) on October 17, 2023. In addition, the Company’s management will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit.
Event details:



Jefferies Biotech CNS/Neuro Summit (October 11 – 12, 2023)

Date: October 11, 2023
Presentation time: 2:00pm EDT / 8:00pm CEST
Venue: New York; NY, USA



Virtual R&D Event with Key Opinion Leaders

Webcasts of the conference presentation and the Virtual R&D Event will be available via the “Presentations & Webcasts” page in the Investor Relations section on the Company’s website at www.vivoryon.com and will be archived on the Company’s website for 90 days (conference), respectively one year (R&D Event) following the events.

###



About Vivoryon Therapeutics N.V.

Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer’s disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com






Vivoryon Forward Looking Statements


This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of the Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.






For more information, please contact:

Investor Contact
Stern IR
Julie Seidel
Tel: +1 212-698-8684
Email: [email protected]

Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: [email protected]

Attachment



‘Tis the Season for Millions of Early Holiday Deals During Prime Big Deal Days

 ‘Tis the Season for Millions of Early Holiday Deals During Prime Big Deal Days

Shop Amazon-exclusive seasonal decor starting as low as $6, everyday value items like coffee makers starting at $8, and apparel from Amazon Essentials under $15, including pajamas for the whole family, fleece jackets for kids, and cold weather accessories

Score deep discounts on Invite-only deals, like 60% off 50-inch Fire TV smart TVs from Amazon and Hisense, and other select items trending this fall and winter—including savings of up to 50% off Sony, up to 40% off Ninja, and 30% off LEGO—and Amazon’s lowest prices of the year so far on select products from PicassoTiles, Clarins, and Peloton

Save on celebrity brand favorites, including Betty Buzz by Blake Lively, Cookware by Martha Stewart, and Ayesha Curry Home Collection, and discover early holiday gifting recommendations curated by Kris Jenner and influencers like Marianna Hewitt, Tayshia Adams, and Leena Snoubar

SEATTLE–(BUSINESS WIRE)–
(NASDAQ: AMZN)—Starting October 10 at 3 a.m. EDT, Prime Big Deal Days will offer some of Amazon’s best savings of the holiday season, exclusively for Prime members, including millions of deals worldwide and even more deals than last year’s October holiday kick-off event. Prime members can come back often to shop items with new deals dropping as often as every five minutes during select periods throughout the event across a wide selection of products with fast and convenient delivery options. Customers who are not yet Prime members and want to get the most out of Amazon can join or start a 30-day free trial at amazon.com/primebigdealdays.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231004270840/en/

(Graphic: Amazon)

(Graphic: Amazon)

Amazon makes it easier for Prime members to find deals they’re interested in with personalized recommendations. Members can now find personalized deals across Amazon, including on products they’ve previously purchased with the “Buy Again” deals feed, customized deals lists based on what they’ve previously saved to their Lists, and deals recommendations based on their browsing history with “Keep shopping for.” Additionally, Inspire on the Amazon Shopping app and Shop by Interest help customers discover deals and explore products with shoppable photos and videos created by influencers, other customers, and brands.

Deals Preview

Prime Big Deal Days will offer savings across top categories, including electronics, toys, home, fashion, beauty, and Amazon devices. Prime members can save big by shopping more than a million deals from independent sellers in Amazon’s store, including TheraGun/TheraFace, Kopari, Proof Culture, Scotch Porter, and Kroma Wellness. It’s also easier than ever for members to discover deals from small businesses, including independent artisans and Black-owned, women-owned, and military-family-owned brands, at amazon.com/smallbusinessdeals. Throughout the deals event, members can look for the Small Business badge and try the new Small Business Search filter to find unique products from small businesses in Amazon’s store. Prime members can also discover and shop more sustainable products as part of the Climate Pledge Friendly program, including deals on The Honest Company, Logitech, Samsung, Seventh Generation, and The Children’s Place.

To take advantage of deals expected to sell out fast during Prime Big Deal Days, Prime members can sign up now for Invite-only deals at an exclusive deal price before the event begins. These include 60% off the 50-inch Amazon Fire TV Omni Series, the Hisense 50-inch U6 4K QLED Fire TV, and Blink smart home security, and additional savings across brands like SodaStream, Citizen, and Jabra. For more information, visit amazon.com/primebigdealdays.

Prime members also can shop deals beyond Amazon.com with Buy with Prime—a new benefit that allows millions of U.S.-based Prime members to shop directly from merchants’ online stores with the convenient and trusted experience they expect from Amazon—including fast, free delivery, a seamless checkout experience, and free returns on eligible orders. Deals include up to 40% off Wyze’s products like the Wyze Cam Floodlight Cam and Wyze Cam v3-3pk; 30% off KNOW Beauty’s newest face mask product, the Arctic Gold Vitamin C Mask; and 20% off Bearaby’s weighted blankets. Learn more at buywithprime.amazon.com/shoppers.

Below is a first look at some of the best deals Prime members will be able to shop early on Amazon and check off their holiday lists. Prime members can set up personalized deal alerts in advance through the Prime Big Deal Days event page on the Amazon Shopping app.

  • Save up to 65% on select eero Mesh Wifi Systems; up to 60% on select Fire TV and Blink devices; up to 50% on select Ring bundles; up to 45% on select kids devices and bundles, select Echo bundles, and select Fire tablet bundles; and up to 35% on select Kindle e-reader bundles

  • Save up to 60% on select floorcare from Bissell and iRobot

  • Save up to 60% on select, Amazon-exclusive apparel, shoes, accessories, and handbags from The Drop

  • Save up to 55% on select ASICS women’s and men’s running shoes

  • Save up to 50% on select products from Sony

  • Save up to 50% on select GreenPan cookware

  • Save up to 50% on select shoes from Hey Dude, Koolaburra by UGG, and Frye

  • Save up to 40% on select Ninja blenders, cookware, and coffee makers

  • Save up to 35% on select Molekule air purifiers

  • Save up to 30% on select KitchenAid stand and mini stand mixers

  • Save up to 30% on select Dyson vacuums and air purifiers

  • Save up to 30% on select premium skincare and haircare products from Clarins, Color Wow, Innisfree, Living Proof, T3, Sunday Riley, LANEIGE, Sulwhasoo, and AMOREPACIFIC

  • Save up to 30% on select dolls, sets, and toys from Barbie, LEGO, Squishmallows, Squishville, PicassoTiles, and MAGNA-TILES

  • Save up to 30% on Peloton Bike, Bike+, Guide, accessories, and select apparel

  • Save up to 30% on select camera items and accessories from Fujifilm

  • Save up to 30% on select non-alcoholic beverages from Betty Buzz by Blake Lively and Kin Euphorics by Bella Hadid and Jen Batchelor

  • Save up to 30% on select kitchenware items from the Ayesha Curry Home Collection

  • Save up to 30% on select, Amazon-exclusive men’s, women’s, and kids’ fashion from Amazon Essentials and Simple Joys by Carter’s

  • Save up to 30% on seasonal prep and decor items, including wreaths, garlands, candles, decorative lights, and Halloween costumes

  • Save up to 30% on select Stasher reusable bags and bowls

  • Save up to 25% on select mattresses from Casper

  • Save up to 25% on select laptops and monitors from HP and Acer

  • Save 20% when spending $40 on select everyday essentials from Amazon brands

  • Save up to 15% on select Cookware by Martha Stewart

  • Save up to 15% (up to $200) on Pre-Loved items from What Goes Around Comes Around, including styles by Louis Vuitton, Chanel, and Gucci

More Ways to Shop & Save

Prime Big Deal Days will offer Prime members additional opportunities to save more on early holiday deals, find shopping inspiration, and earn rewards. Customers can join Prime to participate and:

  • Explore Amazon’s Holiday Shop: Prime members can check out Amazon’s newly launched Holiday Shop to discover seasonal essentials and unique gifts for everyone on their list, all at low prices. Visit amazon.com/holiday to shop the popular Holiday Toy List and get inspiration from some of the top trending gifts—updated on a weekly basis through December 23—and from top-rated Customers’ Most-Loved items. Members can also explore unique gift ideas in the Small Business Gift Guide, which features curated product selections, including those Under $50, Under $25, Black-owned, and women-owned.
  • Shop celebrity and influencer holiday picks: Prime members can shop some of the best early holiday deals through storefronts curated by popular celebrities and influencers, including Kris Jenner, Marianna Hewitt, Tayshia Adams, Rocky Barnes, Leena Snoubar, and Lauren Wolfe.
  • Save big on specialty gift cards: Prime members will have access to Lightning Deals, promotional credit offers, and instant savings with up to 20% off select specialty brands. Over 30 brands will participate, including DoorDash, Panera Bread, and Old Navy.
  • Earn more rewards with Prime Visa and Prime Store Card: During Prime Big Deal Days, members with a Prime Visa or Prime Store Card can earn an extra 1% back (for a total of 6% back) on their orders when they select No-Rush shipping at checkout. Prime Visa and Prime Store Card members earn 5% back year-round on Amazon.com with an eligible Prime membership. Plus, with daily rewards, earnings can now be redeemed as soon as the next day. Additionally, there is an added sign-up bonus for new eligible Prime Visa cardmembers. From October 10 through October 31, Prime members will receive a $150 Amazon gift card instantly upon approval for the Prime Visa. Visit amazon.com/primevisa to learn more.
  • Enjoy fast, free delivery: U.S. Prime members can rely on Amazon to make life easier with free Same-Day or One-Day Delivery on tens of millions of items and, as always, choose the delivery option that best suits their needs. Same-Day Delivery is currently available to customers in more than 90 U.S. metro areas. Prime members also can find their closest Amazon Locker or Counter for a convenient, secure, free delivery, or choose a delivery day preference with Amazon Day.

Explore the Benefits of Prime

Prime is savings, convenience, and entertainment in one single membership. More than 200 million paid Prime members in 25 countries around the world enjoy access to Amazon’s enormous selection, exceptional value, and fast, free delivery. In the U.S., anyone can join Prime for $14.99 per month or $139 per year, or start a free 30-day trial if eligible at amazon.com/prime and enjoy Prime Video, Amazon Music, Prime Gaming, RxPass, Grubhub+, Amazon Photos, Prime exclusive deals, and more. Additionally, college students can try Prime Student with a six-month trial at amazon.com/joinstudent, then just pay $7.49 per month, or $69 per year. Qualifying government assistance recipients can get Prime Access for $6.99 per month at amazon.com/getprimeaccess. For more information about Prime, including discounted memberships, visit aboutamazon.com/prime.

About Amazon

Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.

Amazon.com, Inc.

Media Hotline

[email protected]

www.amazon.com/pr

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Hispanic Retail Online Retail Consumer

MEDIA:

Logo
Logo
Photo
Photo
(Graphic: Amazon)

Innate Pharma Provides Update on Lacutamab Clinical Program

Innate Pharma Provides Update on Lacutamab Clinical Program

  • Phase 2 TELLOMAK trial fully recruited, final data expected Q4 2023
  • Phase 1b PTCL trial awaiting futility interim analysis, preliminary data expected Q4 2023
  • US FDA places lacutamab IND on partial clinical hold for new patient enrollment following one unexpected severe adverse reaction

MARSEILLE, France–(BUSINESS WIRE)–
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the lacutamab IND leading to a pause in new patient enrollment to the Company’s ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL). The partial clinical hold follows one fatal case of hemophagocytic lymphohistiocytosis (HLH), a rare hematologic disorder. Patients already on study treatment who are deriving clinical benefit may continue treatment after being reconsented.

TELLOMAK, Innate Pharma’s ongoing Phase 2 trial of lacutamab in cutaneous T-cell lymphoma (CTCL), completed enrollment in Q2 2023 (n=170 patients). Enrollment is also completed to the initial cohort (n=20 patients) of the Phase 1b PTCL trial and is awaiting a futility interim analysis to progress to the next stage. Innate Pharma is on track for final data from the Phase 2 TELLOMAK trial and preliminary data on PTCL in Q4 2023.

Patient safety is of paramount importance to us, and we are currently undertaking efforts to address the FDA requests, which include incorporation of risk mitigation and management strategies for hemophagocytic lymphohistiocytosis in ongoing lacutamab studies.” said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma.Additionally, with all patients recruited into the Phase 2 TELLOMAK study, we do not currently anticipate any delay for the TELLOMAK Phase 2 final data due shortly.

About Lacutamab

Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL). Rare cutaneous lymphomas of T lymphocytes have a poor prognosis with few efficacious and safe therapeutic options at advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up 90% of patients with certain aggressive CTCL subtypes, in particular, Sézary syndrome. It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues.

Lacutamab is granted European Medicines Agency (EMA) PRIME designation and US Food and Drug Administration (FDA) granted Fast Track designation for the treatment of patients with relapsed or refractory Sézary syndrome who have received at least two prior systemic therapies.Lacutamab is granted orphan drug status in the European Union and in the United States for the treatment of CTCL.

About TELLOMAK:

TELLOMAK (NCT03902184) is a global, open-label, multi-cohort Phase 2 clinical trial recruiting patients with Sézary syndrome and mycosis fungoides (MF) in the United States and Europe. Specifically:

  • Cohort 1: lacutamab being evaluated as a single agent in approximately 60 patients with Sézary syndrome who have received at least two prior systemic therapies, including mogamulizumab. The Sézary syndrome cohort of the study could enable the registration of lacutamab in this indication.

  • Cohort 2: lacutamab being evaluated as a single agent in patients with MF that express KIR3DL2, as determined at baseline with a Simon 2-stage design.

  • Cohort 3: lacutamab being evaluated as a single agent in patients with MF that do not express KIR3DL2, as determined at baseline, with a Simon-2 stage design.

  • All comers: lacutamab being evaluated as a single agent in patients with both KIR3DL2 expressing and non-expressing MF to explore the correlation between the level of KIR3DL2 expression and treatment outcomes utilizing a formalin-fixed paraffin embedded (FFPE) assay under development as a companion diagnostic.

The trial is now fully enrolled. The primary endpoint of the trial is objective global response rate. Key secondary endpoints are progression-free survival, duration of response, overall survival, quality of life, pharmacokinetics and immunogenicity and adverse events.

About the Phase 1b in PTCL:

The Phase 1b clinical trial (NCT05321147) is investigating lacutamab monotherapy in KIR3DL2-expressing patients with relapsed/refractory PTCL who have received at least one prior systemic therapy (N=20, with futility interim ungating N=20 expansion). The trial is designed to evaluate safety, as well as characterize clinical outcomes, pharmacokinetics and immunogenicity of lacutamab alone in PTCL. Further expansion will be determined based on preliminary efficacy signals.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.

Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on Twitter and LinkedIn.

Information about Innate Pharma shares

ISIN code

Ticker code

LEI

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, the Company’s expectations regarding the timing of data for TELLOMAK Phase 2 clinical trial and Phase 1b PTCL clinical trial and statements concerning the Company’s efforts to address theFDA requests relating to the partial clinical hold. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, Innate Pharma’s ability to address theFDA requests including the incorporation of risk mitigation and management strategies for hemophagocytic lymphohistiocytosis in ongoing lacutamab studies and the effectiveness of such strategies, the timing of release of the TELLOMAK Phase 2 trial final data, the timing of release of the Phase 1b PTCL trial preliminary data, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Investors

Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

[email protected]

Media Relations

NewCap

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

[email protected]

KEYWORDS: Europe United States North America France Maryland

INDUSTRY KEYWORDS: Oncology Health FDA Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

The Year of the Great Recharge: Hilton Trends Report Reveals ‘Rest and Relaxation’ to be Top Driver of Travel Decisions Across Generations in 2024

The Year of the Great Recharge: Hilton Trends Report Reveals ‘Rest and Relaxation’ to be Top Driver of Travel Decisions Across Generations in 2024

Report Predicts Travelers of All Ages will Value Connectivity and Personalization, Seek Out Culture and Unique Experiences, and Embrace New Business Travel Trends as Travel Boom Continues

MCLEAN, Va.–(BUSINESS WIRE)–
According to a recent global survey conducted by Hilton and Ipsos, travelers say they will reduce other areas of personal spending to prioritize leisure travel in 2024, with a majority across generations indicating their No. 1 reason to travel in 2024 will be to rest and recharge, with more emphasis on sleep than ever before. Those insights and more were unveiled today with the launch of Hilton’s third-annual trends report: What Millennials, Gen Z, Gen X and Baby Boomers Tell Us About Travel in the Year Ahead.” In addition to defining the preferences and passions of the 2024 traveler, the report takes a deeper look at how each generation views travel – from the digital-native Gen Zer to the experienced Baby Boomer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231004090692/en/

“In this new golden age of travel, travelers’ needs are changing, and we are always innovating to better serve our guests and be their first choice when they hit the road,” said Chris Nassetta, president and chief executive officer, Hilton. “Across generations, we’re seeing guests customize their stays with us, invest in quality sleep, pursue new cultural experiences, and stretch the boundaries of business travel. At Hilton, our world-class team members are leaning into these trends and creating unforgettable experiences for every guest who stays with us.”

Following a global survey of more than 10,000 travelers from nine countries, video diaries with 60 U.S. travelers and in-depth interviews with dozens of Hilton travel experts, the report uncovers four themes expected to be the catalysts of change and innovation for travel in 2024 and beyond.

Travelers Will Invest in Their Sleep

Personal wellness matters to travelers, and even more specifically, there will be an increased focus on savoring a good night’s sleep while away from home – a trend that has accelerated after the challenges of the last few years heightened travelers’ desire for rest and relaxation. In 2024, travelers will look to engage with products and brands aligned with this better-for-you imperative. Gen Zers are the most intentional about winding down, making small choices throughout the day that can make a big impact on their sleep. In fact, 21% regulate their workout routine, and 25% avoid alcohol before bedtime.

Travelers Will Value Connectivity and Personalization

In 2024, travelers will seek out consistent and seamless experiences that are hyper-personalized to their needs, from booking to on-property experiences. Eighty percent of global travelers surveyed said it’s important to be able to book their trip entirely online, with 86% of Millennials and 83% of Gen Zers leading the charge – and 76% of global travelers said they appreciate travel apps that reduce the friction and stress of travel.

Culture and Experiences Will Drive Leisure Travel Decisions

Dining, culture and connections are inspiring leisure travel decisions as people increasingly prioritize the purchase of experiences over things. In fact,as the world holds onto their renewed sense of wanderlust following the pandemic, 64% of global travelers say they aim to reduce other areas of their personal spending to prioritize leisure travel in 2024.

As they budget for 2024, travelers’ top focus is on culinary experiences. Second to culinary experiences, 47% of travelers will prioritize exploration and adventure, with Gen Zers and Millennials (52% for both) carving out more budget for these types of experiences than the other generations.

Business Travel Trends Will Redefine Expectations

Ways of work have transformed significantly following the pandemic – including shifts in when, where and how people conduct business. As a result, business trends have emerged and strengthened, including blended leisure and business travel, increased length of stays and the rising popularity of secondary markets for meetings and events. In fact, more than a third of Gen Z and Millennial business travelers say they plan to extend a business trip to enjoy leisure time before or after their work obligations, and 24% of global business travelers plan to take a friend or family member with them on a business trip next year.

“Every generation is driving a vibrant mix of travel experiences and expectations for 2024,” said Jason Dorsey, president of The Center for Generational Kinetics and Hilton’s generational consultant for this year’s report. “One important finding within is the cross-generational priority for connectivity and personalization throughout the travel experience. This bodes well for fueling innovation in the travel industry and for travel leaders, like Hilton, that are creating new and unique experiences that attract all four generations of adult travelers.”

For more information on how Hilton is staying ahead of travel trends, read the full 2024 report at Stories.Hilton.com/2024trends. To start planning 2024 travel, visit Hilton.com.

Methodology

Both qualitative and quantitative methods were used to determine the emerging trends detailed in this report. Hilton conducted stakeholder interviews across the organization to gain perspectives on what travel looks like today and determine what is top of mind going into 2024, with business divisions including: Business Travel/Events, Food & Beverage, Wellness, Sustainability, Design, Digital Innovation and Workplace Culture. Hilton commissioned two phases of research with Ipsos, one of the largest market research and polling companies globally. First, Ipsos conducted 60 qualitative online video diaries in the U.S. between April and May 2023. Then Ipsos fielded a quantitative online survey in July 2023 among a nationally representative sample in Germany, Great Britain, Japan and the U.S. of adults under age 75. The samples in China, India, Mexico, Singapore and U.A.E. are more urban, more educated and/or more affluent than the general population. The survey results for these markets should be viewed as reflecting the views of the more “connected” segment of their population. Each country included an oversample of n=200 Gen Z to increase analytic capability for this age group. The age breakdown used is Gen Z: 18-26, Millennial: 27-44, Gen X: 45-58 and Baby Boomers: 59-77.

About Hilton

Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 22 world-class brands comprising nearly 7,300 properties and more than 1.1 million rooms, in 123 countries and territories. Dedicated to fulfilling its founding vision to fill the earth with the light and warmth of hospitality, Hilton has welcomed more than 3 billion guests in its more than 100-year history, earned a top spot on Fortune’s 100 Best Companies to Work For list and been recognized as a global leader on the Dow Jones Sustainability Indices for six consecutive years. Hilton has introduced several industry-leading technology enhancements to improve the guest experience, including Digital Key Share, automated complimentary room upgrades and the ability to book confirmed connecting rooms. Through the award-winning guest loyalty program Hilton Honors, the more than 165 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy. With the free Hilton Honors app, guests can book their stay, select their room, check in, unlock their door with a Digital Key and check out, all from their smartphone. Visit stories.hilton.com for more information, and connect with Hilton on Facebook, Twitter, LinkedIn, Instagram and YouTube.

Colleen Hart

Global Corporate Communications

[email protected]

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Tourist Attractions Generation Z Generation X Other Travel Transportation Lodging Destinations Travel Women Baby Boomers Seniors Millennials Men Vacation Consumer

MEDIA:

Logo
Logo

EVI Industries Reports Record Fourth Quarter and Record Fiscal Year Results on 32% Growth, and Announces Special Cash Dividend

EVI Industries Reports Record Fourth Quarter and Record Fiscal Year Results on 32% Growth, and Announces Special Cash Dividend

MIAMI–(BUSINESS WIRE)–
EVI Industries, Inc. (NYSE American: EVI) announced today record results in key financial metrics for the fourth fiscal quarter and the fiscal year ended June 30, 2023. The Company provided commentary on growth opportunities, its financial position, technology initiatives, and industry fundamentals. Click here to listen to the Company’s recorded earnings conference call or visit the “Investors” section of the Company’s website at www.evi-ind.com.

Through disciplined execution of its buy-and-build growth strategy and a thriving entrepreneurial culture, EVI has established itself as a leader in the highly fragmented North American commercial laundry distribution and services market. Since 2016, EVI has, among other things, completed twenty-five acquisitions, expanded into new geographies, retained and invested in additional sales and service personnel, broadened its OEM representations, and implemented advanced operating technologies. As a result of these initiatives, since 2016 EVI’s revenue, net income, and Adjusted EBITDA have grown at compounded annual growth rates (CAGRs) of 39%, 28%, and 37%, respectively, and over this period, EVI has experienced a 7.0% organic revenue CAGR for businesses it has owned for at least three years.

The Company also announced today that its Board of Directors has declared a special cash dividend on the Company’s common stock of $0.28 per share to be paid on October 26, 2023, to stockholders of record at the close of business on October 16, 2023.

Summary of the Company’s Fiscal 2023 Achievements

  • Record results in key financial metrics, including a 32% increase in revenue year over year.

  • Maintained a strong customer sales order backlog as of June 30, 2023, despite record revenues.

  • Sustained a healthy balance sheet with $29 million of net debt as of June 30, 2023.

  • Generated $7.6 million in cash flow from operations during the fourth fiscal quarter.

  • Completed four acquisitions.

Henry M. Nahmad, EVI’s Chairman and CEO, commented: “Our achievements to date are the product of our entrepreneurial leadership team that is thoughtful, collaborative, and committed in the pursuit of our goals. While we are still early in our long-term growth plans, the strength of our team and their successes as demonstrated by our Company’s consistent growth, performance, and financial strength, provide great confidence in our ability to achieve our long-term growth and profitability goals.”

Fiscal Fourth Quarter Results (compared to the fourth quarter of fiscal 2022)

  • Revenue increased 14% to a record $94.0 million.

  • Gross profit increased 25% to a record $27.8 million.

  • Gross margin increased 270 basis points to a record 29.5%.

  • Operating income increased 57% to a record $4.0 million.

  • Net income increased 26% to $1.9 million, approximately 2.0%.

  • Diluted earnings per share increased to $0.13.

  • Adjusted EBITDA increased 39% to a record $6.4 million, approximately 6.8%.

Fiscal Year 2023 Results (compared to fiscal 2022)

  • Revenue increased 32% to a record $354.2 million.

  • Gross profit increased 41% to a record $103.7 million.

  • Gross margin improved 170 basis points to a record 29.3%.

  • Operating income increased 158% to a record $16.5 million.

  • Net income increased 137% to a record $9.7 million, approximately 2.7%.

  • Diluted earnings per share increased to a record $0.67.

  • Adjusted EBITDA increased 80% to a record $25.6 million, approximately 7.2%.

Drivers of Record Sales and Operating Performance

The Company’s record $354 million in revenue for fiscal 2023 reflects the performance of acquired businesses and organic growth at legacy businesses, a more consistent fulfillment of confirmed customer sales order contracts from the Company’s backlog, the completion of on-demand sales fulfilled from a larger available base inventory, and recurring demand for replacement parts and accessories. Additionally, the increased readiness of customer locations to accept installations accelerated the speed with which the Company was able to complete the customer sales order fulfillment process as compared to fiscal 2022. These factors combined with continuous demand for the products and services the Company provides across all four commercial laundry categories and all end customer markets contributed to record revenue in all four fiscal quarters and record revenue for fiscal 2023.

As the Company previously described, manufacturers of commercial laundry products experienced inflationary pressures and raised prices accordingly. Since the onset of this inflationary trend in June 2020, the Company raised selling prices and took other measures aimed to improve gross margins. These actions resulted in a 590 basis-point increase in gross margins from 23.4% at fiscal year-end 2020 to 29.3% at fiscal year-end 2023. While the significant increase in gross margins has been a catalyst for driving improved operating profit, the Company’s ongoing modernization investments and optimization initiatives, including successful efforts to regionalize operations and implement new technologies at legacy business units, also had a positive impact on operating profit. These investments and initiatives are designed to reduce costs, enhance efficiency, and promote consistency across the Company’s operations and result in a more agile and responsive organization capable of scaling up with continued growth. Although these fundamental initiatives in connection with legacy business units is nearing completion, this is expected to be a perpetual effort in light of the buy-component of the Company’s growth strategy.

Financial Strength and Liquidity

EVI’s strong financial position has enabled simultaneous investments in acquisitions, organic growth, working capital, and technological innovations. Since June 30, 2021, EVI’s working capital more than tripled to nearly $50 million and the Company deployed approximately $19 million of capital in connection with acquisitions. Despite these investments, EVI’s financial position remains strong with low leverage and the ability to simultaneously invest in various buy-and-build opportunities. As of June 30, 2023, the Company had net debt of $29 million, with net income and Adjusted EBITDA for fiscal 2023 of approximately $10 million and $26 million, respectively. The Company believes this financial strength, access to low-cost capital and its historical ability to generate cash flow provide comfort and confidence to the Company’s stakeholders.

Cash Flow and Special Cash Dividend

Cash provided by operations was $7.6 million and approximately $1 million for the fourth fiscal quarter and fiscal 2023, respectively. EVI’s operating cash flow for fiscal 2023 reflects the continued build-up of working capital started in June 2021 with the advanced placement of product orders in connection with confirmed customer sales orders in the Company’s backlog and stock orders required to fulfill on-demand customer orders amid the continuation of an inefficient supply chain as compared to historical. While the speed of the customer order fulfillment process is not yet where it once was, the Company’s OEM’s and vendors have improved lead times and external parties responsible for preinstallation preparations are increasingly performing on schedule. Accordingly, the Company does not currently expect further significant investment in working capital in the near-term, which it expects will positively benefit future cash flow from operations.

On October 4, 2023, the Company’s Board of Directors declared a special cash dividend on the Company’s common stock of $0.28 per share to be paid on October 26, 2023 to stockholders of record at the close of business on October 16, 2023.

Mr. Nahmad commented: “Our strong fiscal 2023 performance allows us the opportunity to reward those who are invested in our long-term strategy, and it reflects the confidence we have in our business outlook, which is supported by our strong balance sheet.”

The Company has considered, and will continue to consider, the payment of dividends to share cash flow while maintaining a conservative financial position with continued capacity to build its distribution and service network. Future dividends will be considered in light of investment opportunities, general economic conditions, the Company’s liquidity and overall financial position.

Acquisitions

During fiscal 2023, the Company completed the acquisition of four commercial laundry distributors and service providers (K&B Laundry Service, Aldrich Clean-Tech Equipment, Wholesale Commercial Laundry Equipment, and Express Parts and Services). In each case, EVI added experienced sales professionals with a track record of growth across an established customer base and a team of knowledgeable service technicians with a longstanding reputation for providing reliable services.

Mr. Nahmad commented: “We continue to identify and pursue many acquisitions and strategic transactions in the commercial laundry industry and across a wide range of exciting and available opportunities in related industries. We believe that our expansion through acquisitions and other strategic transactions is integral to our ability to achieve our long-term growth goals and given our Company’s reputation, growth record, financial resources, entrepreneurial culture, and long-term growth plans, we believe that the EVI family of businesses will continue to grow.”

Industry Fundamentals

The attractiveness of the commercial laundry industry is evidenced by decades of consistent demand for commercial laundry products and services driven by steady growth experienced across all end customer markets, including, but not limited to, healthcare, hospitality, food service, institutional, vended, and multifamily. Commercial laundries that serve these end markets require advanced planning, thoughtful design, knowledgeable installation, and continuous post-installation service and support. Given the varying complexity of such laundry operations and that clean laundry is the essential service provided by such businesses, customers need the products and services a distributor and service company provide to deliver clean linens effectively and profitably to the end users they serve. Demand for commercial laundry products and services is also driven by functional and economic obsolescence. Specifically, demand has increased due to the introduction of new equipment with advanced technologies that yield attractive returns on invested capital derived from water, energy, and labor savings.

To best address the various industry growth opportunities, the Company serves as both distributor and service provider. EVI’s sales organization has continued to grow and, to the Company’s knowledge, now represents the single largest sales organization in the commercial laundry industry, representing the broadest range of commercial laundry and related products sourced from various domestic and international suppliers. With these products, the Company’s sales organization creates laundry solutions predominantly for the replacement and new construction markets for industrial, on-premise, vended, and multifamily laundry applications. The Company also has the single largest and growing network of technicians responsible for the proper installation of such laundries and capable of servicing and supporting commercial laundry facilities throughout its useful life.

Given the Company’s position in the industry value chain, specifically the fact that it owns the end customer relationship, the Company can increasingly capitalize on its visibility to numerous complementary products and services its customers purchase for their laundry operations from other businesses, most of which represent long-term growth opportunities for the Company. The Company believes that the time-tested fundamentals and favorable attributes of the commercial laundry industry combined with the Company’s long-term growth strategy, financial strength, entrepreneurial culture, technology initiatives, and strong supplier relations are important competitive advantages that support the Company’s ability to grow and capture more profitable market share going forward.

EVI’s Core Principles

The Company upholds specific core values and principles for its business, including:

  • Invest and manage with a long-term perspective.

  • Uphold financial discipline with a view towards ensuring financial strength and flexibility.

  • Respect the entrepreneurs and management teams that join the EVI family.

  • Operate as a local business and empower leaders to make local decisions.

  • Promote an entrepreneurial culture.

  • Instill a growth mindset and culture of continuous improvement.

  • Incentivize and reward performance with equity participation.

  • Establish strong relationships with OEM partners.

Mr. Nahmad further added: “Our strategy is long-term focused, and it takes time, patience, and thoughtful execution to achieve our goals. We continue to pursue acquisition and other strategic opportunities in the commercial laundry industry and across other product and service categories that meet our financial and strategic criteria. While we are pleased with our operating performance, we are steadfast in our pursuit of growth in the execution of our long-term buy-and-build growth strategy.”

Use of Non-GAAP Financial Information

In this press release, EVI discloses the non-GAAP financial measure of Adjusted EBITDA, which EVI defines as earnings before interest, taxes, depreciation, amortization, and amortization of share-based compensation. Adjusted EBITDA is determined by adding interest expense, income taxes, depreciation, amortization, and amortization of share-based compensation to net income, as shown in the attached statement of Condensed Consolidated Earnings before Interest, Taxes, Depreciation, Amortization, and Amortization of Share-based Compensation. EVI considers Adjusted EBITDA to be an important indicator of its operating performance. Adjusted EBITDA is also used by companies, lenders, investors and others because it excludes certain items that can vary widely across different industries or among companies within the same industry. For example, interest expense can be dependent on a company’s capital structure, debt levels and credit ratings, and the tax positions of companies can vary because of their differing abilities to take advantage of tax benefits and because of the tax policies of the jurisdictions in which they operate. Adjusted EBITDA should not be considered as an alternative to net income or any other measure of financial performance or liquidity, including cash flow, derived in accordance with GAAP, or to any other method of analyzing EVI’s results as reported under GAAP. In addition, EVI’s definition of Adjusted EBITDA may not be comparable to definitions of Adjusted EBITDA or other similarly titled measures used by other companies.

About EVI Industries

EVI Industries, Inc., through its wholly owned subsidiaries, is a value-added distributor and a provider of advisory and technical services. Through its vast sales organization, the Company provides its customers with planning, designing, and consulting services related to their commercial laundry operations. The Company sells and/or leases its customers commercial laundry equipment, specializing in washing, drying, finishing, material handling, water heating, power generation, and water reuse applications. In support of the suite of products it offers, the Company sells related parts and accessories. Additionally, through the Company’s robust network of commercial laundry technicians, the Company provides its customers with installation, maintenance, and repair services. The Company’s customers include retail, commercial, industrial, institutional, and government customers. Purchases made by customers range from parts and accessories to single or multiple units of equipment, to large complex systems as well as the purchase of the Company’s installation, maintenance, and repair services.

Safe Harbor Statement

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward looking statements may relate to, among other things, events, conditions, and trends that may affect the future plans, operations, business, strategies, operating results, financial position and prospects of the Company. Forward looking statements are subject to a number of known and unknown risks and uncertainties that may cause actual results, trends, performance or achievements of the Company, or industry trends and results, to differ materially from the future results, trends, performance or achievements expressed or implied by such forward looking statements. These risks and uncertainties include, among others, those associated with: general economic and business conditions in the United States and other countries where the Company operates or where the Company’s customers and suppliers are located, including the potential of a recession; industry conditions and trends; credit market volatility; risks related to supply chain delays and disruptions and their impact on the Company’s business and results, including the Company’s ability to deliver products and services to its customers on a timely basis and the risk that further significant investment in working capital may be required and that any decrease in investment in working capital may not positively benefit the Company’s cash flow from operations to the extent anticipated or at all; risks relating to inflation, including the current inflationary trend, and the impact of inflation on the Company’s costs and its ability to increase the price of its products and services to offset such costs, and on the market for the Company’s products and services; risks related to labor shortages and increases in the costs of labor, and the impact thereof on the Company, including its ability to deliver products, provide services or otherwise meet customers’ expectations; risks related to interest rate increases, including the impact thereof on the cost of the Company’s indebtedness and the Company’s ability to raise capital if deemed necessary or advisable; risks associated with international relations and international hostilities, including actions of foreign governments and the impact thereof on economic conditions, including supply chain constraints and inflationary trends; the Company’s ability to implement its business and growth strategies and plans, including changes thereto; risks and uncertainties associated with the Company’s ”buy-and-build” growth strategy, including, without limitation, that the Company may not be successful in identifying or consummating acquisitions or other strategic transactions, integration risks, risks related to indebtedness incurred by the Company in connection with the financing of acquisitions and other strategic transactions, dilution experienced by the Company’s existing stockholders as a result of the issuance of shares of the Company’s common stock in connection with acquisitions or other strategic transactions (or for other purposes), risks related to the business, operations and prospects of acquired businesses, risks that suppliers of the acquired business may not consent to the transaction or otherwise continue its relationship with the acquired business following the transaction and the impact that the loss of any such supplier may have on the results of the Company and the acquired business, risks that the Company’s goals or expectations with respect to acquisitions and other strategic transactions may not be met, and risks related to the accounting for acquisitions; risks relating to the impact of pricing concessions and other measures which the Company may take from time to time in connection with its expansion efforts and pursuit of market share growth, including that they may not be successful and may adversely impact the Company’s gross margin and other financial results; technology changes; competition, including the Company’s ability to compete effectively and the impact that competition may have on the Company and its results, including the prices which the Company may charge for its products and services and on the Company’s profit margins, and competition for qualified employees; to the extent applicable, risks relating to the Company’s ability to enter into and compete effectively in new industries, as well as risks and trends related to those industries; risks relating to the Company’s relationships with its principal suppliers and customers, including the impact of the loss of any such relationship; the risk that orders in the Company’s backlog may not be fulfilled as or when expected; risks related to organic growth initiatives and market share and other growth strategies, including that they may not result in the benefits anticipated; risks that investments, initiatives and expenses, including, without limitation, investments in acquired businesses and modernization initiatives, technology integration initiatives, expenses associated with the Company’s implementation of its enterprise resource planning system, and other investments, initiatives and expenses, may not result in the benefits anticipated and may take longer than expected or be more costly than expected; the risk that the Company’s performance and results, including revenues, net income and adjusted EBITDA may not continue to improve, and the Company may not achieve growth consistent with historical levels, at the level expected, or at all; dividends may not be declared in the future; and other economic, competitive, governmental, technological and other risks and factors discussed elsewhere in the Company’s filings with the SEC, including, without limitation, in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023, as filed with the Securities and Exchange Commission on or about the date hereof.. Many of these risks and factors are beyond the Company’s control. Further, past performance and perceived trends may not be indicative of future results. The Company cautions that the foregoing factors are not exclusive. The reader should not place undue reliance on any forward-looking statement, which speaks only as of the date made. The Company does not undertake to, and specifically disclaims any obligation to, update, revise or supplement any forward-looking statement, whether as a result of changes in circumstances, new information, subsequent events or otherwise, except as may be required by law.

EVI Industries, Inc.

Condensed Consolidated Results of Operations (in thousands, except per share data)

 

 

 

 

 

Unaudited

Unaudited

 

12-Months Ended

12-Months Ended

3-Months Ended

3-Months Ended

06/30/23

06/30/22

06/30/23

06/30/22

 

 

Revenues

$ 354,173

$ 267,316

$ 94,041

$ 82,831

Cost of Sales

250,490

193,609

66,253

60,632

Gross Profit

103,683

73,707

27,788

22,199

SG&A

87,177

67,318

23,774

19,638

Operating Income

16,506

6,389

4,014

2,561

Interest Expense, net

2,507

679

788

289

Income before Income Taxes

13,999

5,710

3,226

2,272

Provision for Income Taxes

4,280

1,615

1,328

764

Net Income

$ 9,719

$ 4,095

$ 1,898

$ 1,508

 

 

Net Earnings per Share

 

 

Basic

$ 0.68

$ 0.30

$ 0.13

$ 0.11

Diluted

$ 0.67

$ 0.29

$ 0.13

$ 0.11

 

 

 

Weighted Average Shares Outstanding

 

 

 

Basic

12,553

12,367

12,575

12,505

Diluted

12,804

12,650

12,959

12,513

 

 

 

 

 

EVI Industries, Inc.

Condensed Consolidated Balance Sheets (in thousands, except per share data)

 

 

 

 

 

06/30/23

06/30/22

Assets

 

Current assets

 

 

 

Cash and cash equivalents

 

$ 5,921

$ 3,974

Accounts receivable, net

 

48,391

43,014

Inventories, net

 

59,167

49,359

Vendor deposits

 

2,291

1,728

Contract assets

 

1,181

1,519

Other current assets

 

8,547

6,018

Total current assets

 

125,498

105,612

Equipment and improvements, net

 

12,953

13,033

Operating lease assets

 

8,714

7,480

Intangible assets, net

 

24,128

26,234

Goodwill

 

73,388

71,039

Other assets

 

9,166

7,370

Total assets

 

$ 253,847

$ 230,768

 

 

 

 

Liabilities and Shareholders’ Equity

 

 

 

Current liabilities

 

 

 

Accounts payable and accrued expenses

 

$ 38,730

$ 42,026

Accrued employee expenses

 

10,724

8,508

Customer deposits

 

23,296

21,288

Contract liabilities

 

668

507

Current portion of operating lease liabilities

 

3,027

2,518

Total current liabilities

 

76,445

74,847

Deferred income taxes, net

 

5,023

4,666

Long-term operating lease liabilities

 

6,554

5,736

Long-term debt, net

 

34,869

27,840

Total liabilities

 

122,891

113,089

 

 

 

 

Shareholders’ equity

 

 

 

Preferred stock, $1.00 par value

 

Common stock, $.025 par value

 

318

316

Additional paid-in capital

 

101,225

97,544

Treasury stock

 

(3,195)

(3,070)

Retained earnings

 

32,608

22,889

Total shareholders’ equity

 

130,956

117,679

Total liabilities and shareholders’ equity

 

$ 253,847

$ 230,768

 

 

 

 

EVI Industries, Inc.

Condensed Consolidated Statements of Cash Flows (in thousands)

 

For the twelve months ended

 

 

06/30/23

06/30/22

Operating activities:

 

Net income

 

$ 9,719

$ 4,095

Adjustments to reconcile net income to net cash provided (used) by operating activities:

 

 

 

Depreciation and amortization

 

6,024

5,209

Amortization of debt discount

 

29

133

Provision for bad debt expense

 

710

446

Non-cash lease expense

 

93

136

Stock compensation

 

3,062

2,598

Inventory reserve

 

(178)

(105)

Provision (benefit) for deferred income taxes

 

357

(164)

Other

 

(103)

(24)

(Increase) decrease in operating assets:

 

 

 

Accounts receivable

 

(5,664)

(12,139)

Inventories

 

(8,302)

(20,396)

Vendor deposits

 

(527)

(1,191)

Contract assets

 

338

(1,172)

Other assets

 

(4,296)

(433)

(Decrease) increase in operating liabilities:

 

 

 

Accounts payable and accrued expenses

 

(4,164)

13,265

Accrued employee expenses

 

2,114

814

Customer deposits

 

1,567

9,755

Contract liabilities

 

161

(2,725)

Net cash provided (used) by operating activities

 

940

(1,898)

 

 

 

 

Investing activities:

 

 

 

Capital expenditures

 

(3,708)

(3,981)

Cash paid for acquisitions, net of cash acquired

 

(2,278)

(11,953)

Net cash used by investing activities

 

(5,986)

(15,934)

 

 

 

 

Financing activities:

 

 

 

Proceeds from borrowings

 

77,000

65,000

Debt repayments

 

(70,000)

(49,000)

Payment of debt issuance costs

 

(166)

Repurchases of common stock in satisfaction of employee tax withholding obligations

 

(125)

(205)

Issuances of common stock under employee stock purchase plan

 

118

120

Net cash provided by financing activities

 

6,993

15,749

Net increase (decrease) in cash and cash equivalents

 

1,947

(2,083)

Cash and cash equivalents at beginning of period

 

3,974

6,057

Cash and cash equivalents at end of period

 

$ 5,921

$ 3,974

 

 

 

 

 

 

 

 

EVI Industries, Inc.

Condensed Consolidated Statements of Cash Flows (in thousands)

 

 

For the twelve months ended

 

 

06/30/23

06/30/22

Supplemental disclosures of cash flow information:

 

 

 

Cash paid for interest

 

$ 2,469

$ 494

Cash paid for income taxes

 

$ 3,099

$ 430

 

 

 

 

Supplemental disclosures of non-cash financing activities:

 

 

 

Common stock issued for acquisitions

 

$ 503

$ 4,331

 

 

 

 

The following table reconciles net income, the most comparable GAAP financial measure, to Adjusted EBITDA.

EVI Industries, Inc.

Condensed Consolidated Earnings before Interest, Taxes, Depreciation, Amortization, and Amortization of Share-based Compensation (in thousands)

 

 

 

 

 

Unaudited

Unaudited

 

12-Months Ended

12-Months Ended

3-Months Ended

3-Months Ended

06/30/23

06/30/22

06/30/23

06/30/22

 

 

Net Income

$ 9,719

$ 4,095

$ 1,898

$ 1,508

Provision for Income Taxes

4,280

1,615

1,328

764

Interest Expense, Net

2,507

679

788

289

Depreciation and Amortization

6,024

5,209

1,615

1,414

Amortization of Share-based Compensation

3,062

2,598

795

651

Adjusted EBITDA

$ 25,592

$ 14,196

$ 6,424

$ 4,626

 

 

 

 

EVI Industries, Inc.

Henry M. Nahmad

Chairman and CEO

(305) 402-9300

Investor Relations

(305) 402-9300

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Consulting Manufacturing Other Manufacturing Professional Services Machinery

MEDIA:

Grupo Aeroportuario del Pacifico Announces Government Action to Change Tariff Base Regulation

GUADALAJARA, Mexico, Oct. 04, 2023 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”). On October 4, 2023, GAP received a notification from the Federal Civil Aviation Agency (Agencia Federal de Aviación Civil, “AFAC”), a decentralized entity of the Mexican Secretary of Infrastructure, Communications, and Transport (Secretaría de  Infraestructura, Comunicaciones y Transporte, “SICT”), informing that has decided, unilaterally and without any previous communication with the Company, to amend with immediate effect the terms of the tariff base regulation (Bases de Regulación Tarifaria) set forth in Annex 7 of the concession agreements undertaken with the SICT on June 29, 1998, as amended, in connection with the airports GAP operates in Mexico’s Pacific region.

GAP is currently evaluating the potential impact that the changes to the tariff base regulation may have on its business, results of operation, and financial condition.

Company Description

Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali, and Los Mochis. In February 2006, GAP’s shares were listed on the New York Stock Exchange under the ticker symbol “PAC” and on the Mexican Stock Exchange under the ticker symbol “GAP”. In April 2015, GAP acquired 100% of Desarrollo de Concessioner Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the Norman Manley International Airport operation in Kingston, Jamaica, and took control of the operation in October 2019.

  This press release may contain forward-looking statements. These statements are statements that are not historical facts and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance and financial results. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations and the factors or trends affecting financial condition, liquidity or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends or results will actually occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.  
     

In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and Article 42 of the “Ley del Mercado de Valores”, GAP has implemented a “whistleblower” program, which allows complainants to anonymously and confidentially report suspected activities that involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party responsible for collecting these complaints, is 800 04 ETICA (38422) or WhatsApp +52 55 6538 5504. The website is www.lineadedenunciagap.com or by email at [email protected]. GAP’s Audit Committee will be notified of all complaints for immediate investigation.

Alejandra Soto, Investor Relations and Social Responsibility Officer [email protected]
Gisela Murillo, Investor Relations [email protected] /
+52 33 3880 1100 ext. 20294

 



Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

PURCHASE, N.Y., Oct. 04, 2023 (GLOBE NEWSWIRE) — Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today announced that it issued inducement awards to two new employees.

Effective October 1, 2023 and October 2, 2023, in connection with commencing employment, two new non-executive employees of Teladoc Health were granted options to purchase an aggregate of 64,616 shares of Teladoc Health’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price per share of $18.59 and $18.43, respectively, and awards of restricted stock units covering an aggregate of 36,508 shares of Common Stock. The stock options vest, based on continued service to Teladoc Health, as to twenty-five percent of the underlying shares on October 1, 2024, with the remainder of the option vesting monthly over three years thereafter. The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on October 1, 2024, with the remainder vesting quarterly over two years thereafter. The awards were approved by the Compensation Committee of the Board of Directors of Teladoc Health and were granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as employment inducement awards pursuant to New York Stock Exchange Rule 303A.08.

About Teladoc Health

Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com

Media:

Chris Stenrud
860-491-8821
[email protected]



MediciNova Receives Gene Therapy Milestone Payment

LA JOLLA, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi. The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV (adeno-associated virus) vector technology that is covered under the assignment agreement.

About MediciNova

MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in glioblastoma, Long COVID, and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by, or otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “can,” “could,” “may,” “will,” “would,” “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova’s operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova’s collaborations with third parties, the availability of funds to complete product development plans and MediciNova’s ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2022 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.


INVESTOR CONTACT

:

Geoff O’Brien

Vice President

MediciNova, Inc.



[email protected]



Correcting & Replacing — Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium

In a press release issued earlier this afternoon, the time zone of the FPWR Research Symposium presentation was labeled as Central Time. The correct time zone is Mountain Time.

The corrected press release is posted below.

REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced an oral presentation at the Foundation for Prader-Willi Research (FPWR) 2023 Research Symposium, being held October 5-6, 2023, in Denver, Colorado. The presentation features results from the recently completed randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS).

Presentation details can be found below:

FPWR 2023 Research Symposium

Title: Rationale for and Results from a Randomized Withdrawal Period Following Long-Term Administration of Diazoxide Choline Extended-Release Tablets to People with Prader-Willi Syndrome
Presenter: Jennifer L. Miller, M.D. (University of Florida)
Format: Oral Presentation
Date/Time: Thursday, October 5, 2023 at 2:00 – 2:20 PM MDT
Location: Westin, Downtown Denver
Livestream: Click Here



About PWS

The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening feeling of intense, persistent hunger, food pre-occupation, extreme drive to food seek and consume food that severely diminish the quality of life for patients with PWS and their families. Additional characteristics of PWS include behavioral problems, cognitive disabilities, low muscle tone, short stature (when not treated with growth hormone), the accumulation of excess body fat, developmental delays, and incomplete sexual development. Hyperphagia can lead to significant morbidities (e.g., obesity, diabetes, cardiovascular disease) and mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior). In a global survey conducted by the Foundation for Prader-Willi Research, 96.5% of respondents (parent and caregivers) rated hyperphagia and 92.9% rated body composition as either the most important or a very important symptom to be relieved by a new medicine. There are currently no approved therapies to treat the hyperphagia/appetite, metabolic, cognitive function, or behavioral aspects of the disorder.

About DCCR (Diazoxide Choline) Extended-Release Tablets

DCCR is a novel, proprietary extended-release dosage form containing the crystalline salt of diazoxide and is administered once-daily. The parent molecule, diazoxide, has been used for decades in thousands of patients in a few rare diseases in neonates, infants, children and adults, but has not been approved for use in PWS. Soleno conceived of and established extensive patent protection on the therapeutic use of diazoxide, diazoxide choline and DCCR in patients with PWS. The DCCR development program is supported by data from five completed Phase 1 clinical studies in healthy volunteers and three completed Phase 2 clinical studies, one of which was in patients with PWS. In the PWS Phase 3 clinical development program, DCCR showed promise in addressing hyperphagia, the hallmark symptom of PWS, as well as several other symptoms such as aggressive/destructive behaviors, fat mass and other metabolic parameters. Diazoxide choline has received Orphan Drug Designation for the treatment of PWS in the U.S. and E.U., and Fast Track Designation in the U.S.

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of PWS, recently completed its Phase 3 development program to support a planned NDA submission. For more information, please visit www.soleno.life.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the potential receipt of gross proceeds from the warrant financing under the Securities Purchase Agreement, management’s assessment of the top-line data results from the randomized withdrawal period, and the timing and pathway of the regulatory process and clinical development path for seeking approval of DCCR for the treatment of PWS. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “goal,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions, as well as risks and uncertainties inherent in Soleno’s business, including those described in the company’s prior press releases and in the periodic reports it files with the U.S. Securities and Exchange Commission. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Corporate Contact:

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578